The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Johnson A1, Zeng J1, Bailey AM1, Holla V1, Litzenburger B1, Lara-Guerra H1, Mills GB2, Mendelsohn J3, Shaw KR1, Meric-Bernstam F4.

Author information

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.